Full Results to be Presented at European Association for the Study of the Liver (EASL) Annual Meeting

Potential Additional Treatment Strategy to Reduce Liver Damage in Chronic Patients

Novel Mechanism of Action May Yield New Treatment Alternatives for Difficult-to-Treat Neurodegenerative Disorder

Company's Lead Compound MitoQ Targets Mitochondrial Dysfunction

Company Poised to Enter Phase 2 Trials for Parkinson's Disease and Friedreich Ataxia
CEO Dr. Ken Taylor to Speak at BIO April 12th